CellaVision AB Share Price

Equities

CEVI

SE0000683484

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Stockholm 17:00:00 20/06/2024 BST 5-day change 1st Jan Change
262 SEK +3.35% Intraday chart for CellaVision AB +3.56% +23.58%

Financials

Sales 2024 * 772M 73.43M 5.81B Sales 2025 * 888M 84.43M 6.68B Capitalization 6.25B 594M 47.02B
Net income 2024 * 167M 15.88M 1.26B Net income 2025 * 216M 20.54M 1.63B EV / Sales 2024 * 7.93 x
Net cash position 2024 * 127M 12.05M 953M Net cash position 2025 * 214M 20.38M 1.61B EV / Sales 2025 * 6.8 x
P/E ratio 2024 *
37.6 x
P/E ratio 2025 *
28.9 x
Employees -
Yield 2024 *
0.93%
Yield 2025 *
1.14%
Free-Float 82.65%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.35%
1 week+3.56%
1 month+3.76%
3 months+20.18%
6 months+26.88%
Current year+23.58%
More quotes
1 week
251.00
Extreme 251
263.50
1 month
247.00
Extreme 247
282.50
Current year
185.20
Extreme 185.2
282.50
1 year
120.00
Extreme 120
282.50
3 years
120.00
Extreme 120
503.50
5 years
120.00
Extreme 120
503.50
10 years
22.10
Extreme 22.1
503.50
More quotes
Managers TitleAgeSince
Founder 59 15/11/94
Chief Executive Officer 53 20/03/21
Director of Finance/CFO 58 01/05/13
Members of the board TitleAgeSince
Founder 59 15/11/94
Director/Board Member 58 10/05/22
Chairman 62 22/04/20
More insiders
Date Price Change Volume
20/06/24 262 +3.35% 11,576
19/06/24 253.5 -0.59% 2,250
18/06/24 255 0.00% 6,603
17/06/24 255 +0.79% 10,931

Delayed Quote Nasdaq Stockholm, June 20, 2024 at 05:00 pm

More quotes
CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
262 SEK
Average target price
256.2 SEK
Spread / Average Target
-2.19%
Consensus